Organoids are miniature, three-dimensional tissues formed by culturing stem cells with self-organizing and self-renewing capabilities to resemble their source tissues both structurally and functionally. Organoids can be categorized based on their source cells into adult stem cell (AdSCs)-derived organoids, pluripotent stem cell (PSCs)-derived organoids, and tumor organoids.
As a novel research model, organoids can be cultured and passaged in vitro while maintaining the heterogeneity and spatial characteristics of their source tissues. They play a significant role in disease modeling and personalized precision therapy.
Currently, the platform has established various organoid culture systems derived from both clinical tumor tissues and normal tissues. These include:
Urothelial carcinoma organoid culture system and normal urothelial organoid culture system
Lung adenocarcinoma organoid culture system and normal lung organoid culture system
Renal carcinoma organoid culture system and normal renal organoid culture system
Colorectal cancer organoid culture system
Thyroid cancer organoid culture system
Nasopharyngeal carcinoma organoid culture system
Following multi-omics profiling, the established tumor organoids are stored in a biobank. As "substitutes" for tumor patients outside the body, tumor organoids can predict patients' responses to anti-tumor drugs, providing experimental and theoretical support for clinical personalized treatment. By integrating single-cell sequencing and gene editing technologies, this platform allows for exploration of molecular mechanisms underlying tumor development and drug resistance.
